These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 11005508)

  • 1. Escape mechanisms in tumor immunity: a year 2000 update.
    Pawelec G; Heinzel S; Kiessling R; Müller L; Ouyang Q; Zeuthen J
    Crit Rev Oncog; 2000; 11(2):97-133. PubMed ID: 11005508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Escape mechanisms in tumor immunity: an update.
    Müller L; Kiessling R; Rees RC; Pawelec G
    J Environ Pathol Toxicol Oncol; 2002; 21(4):277-330. PubMed ID: 12510961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.
    Algarra I; García-Lora A; Cabrera T; Ruiz-Cabello F; Garrido F
    Cancer Immunol Immunother; 2004 Oct; 53(10):904-10. PubMed ID: 15069585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour escape from the immune response: the last hurdle for successful immunotherapy of cancer?
    Pawelec G
    Cancer Immunol Immunother; 1999 Oct; 48(7):343-5. PubMed ID: 10501845
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumor-host immune interactions and dendritic cell dysfunction.
    Yang L; Carbone DP
    Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression.
    Ahmad M; Rees RC; Ali SA
    Cancer Immunol Immunother; 2004 Oct; 53(10):844-54. PubMed ID: 15197495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commentary: Immune escape versus tumor tolerance: how do tumors evade immune surveillance?
    Salih HR; Nüssler V
    Eur J Med Res; 2001 Aug; 6(8):323-32. PubMed ID: 11549514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immune response and cancer].
    El Hage F; Abouzahr-Rifai S; Meslin F; Mami-Chouaib F; Chouaib S
    Bull Cancer; 2008 Jan; 95(1):57-67. PubMed ID: 18230571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of clonal deletion vs. anergy of self-reactive CD4 T-cells for the prevention and reversal of autoimmune diabetes.
    Preda-Pais A; Stan AC; Casares S; Bona C; Brumeanu TD
    J Autoimmun; 2005 Aug; 25(1):21-32. PubMed ID: 16005609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines.
    Mocellin S; Nitti D
    Med Res Rev; 2008 May; 28(3):413-44. PubMed ID: 17694549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A primer on cancer immunology and immunotherapy.
    Lotze MT; Papamichail M
    Cancer Immunol Immunother; 2004 Mar; 53(3):135-8. PubMed ID: 14740175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phases of apoptosis of melanoma cells, but not of normal melanocytes, differently affect maturation of myeloid dendritic cells.
    Pietra G; Mortarini R; Parmiani G; Anichini A
    Cancer Res; 2001 Nov; 61(22):8218-26. PubMed ID: 11719453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?
    Malmberg KJ
    Cancer Immunol Immunother; 2004 Oct; 53(10):879-92. PubMed ID: 15338206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Escape from host-antitumor immunity.
    Pawelec G; Zeuthen J; Kiessling R
    Crit Rev Oncog; 1997; 8(2-3):111-41. PubMed ID: 9570292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of T cell anergy by the treatment with IL-10-treated dendritic cells.
    Zheng Z; Narita M; Takahashi M; Liu A; Furukawa T; Toba K; Aizawa Y
    Comp Immunol Microbiol Infect Dis; 2004 Mar; 27(2):93-103. PubMed ID: 14690719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens.
    Cuenca A; Cheng F; Wang H; Brayer J; Horna P; Gu L; Bien H; Borrello IM; Levitsky HI; Sotomayor EM
    Cancer Res; 2003 Dec; 63(24):9007-15. PubMed ID: 14695219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-classical HLA-G antigen and its role in the cancer progression.
    Tripathi P; Agrawal S
    Cancer Invest; 2006 Mar; 24(2):178-86. PubMed ID: 16537188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-refractory cancers and their little helpers--an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E?
    Wischhusen J; Waschbisch A; Wiendl H
    Semin Cancer Biol; 2007 Dec; 17(6):459-68. PubMed ID: 17768067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor immunity and immunotherapy.
    Boura P; Kountouras J; Lygidakis NJ
    Hepatogastroenterology; 2001; 48(40):1040-4. PubMed ID: 11490795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer immunogene therapy.
    Yoshizawa H; Kagamu H; Gejyo F
    Arch Immunol Ther Exp (Warsz); 2001; 49(5):337-43. PubMed ID: 11798131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.